September 21, 2023

Entrada Therapeutics starts dosing in ENTR-601-44 Phase 1 trial

Entrada Therapeutics has announced that the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44, the company’s proprietary Endosomal Escape Vehicle (EEV™)-conjugated phosphorodiamidate morpholino oligomer (PMO), for the potential treatment of…

Learn More

December 20, 2022

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne

Entrada Therapeutics has shared that the FDA issued a clinical hold on the Investigational New Drug (IND) application for its ENTR-601-44 program, an exon-skipping therapy set to target individuals with Duchenne amenable to exon 44…

Learn More

May 13, 2022

Entrada Therapeutics Shares New Data on ENTR-601-44 Exon Skipping Therapy

Entrada Therapeutics has shared new data from a preclinical study evaluating ENTR-601-44, an exon-skipping therapy set to target individuals with Duchenne amenable to exon 44 skipping. We are pleased to hear new data on this…

Learn More